<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673878</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC18.0155</org_study_id>
    <nct_id>NCT03673878</nct_id>
  </id_info>
  <brief_title>Prevalence of a Localized or Diffuse Pruritus in a Population With One or Several, Primitive or Secondary, Brain Tumor(s)</brief_title>
  <acronym>PRURI-C</acronym>
  <official_title>Study on the Prevalence of a Localized or Diffuse Pruritus in a Population With One or Several, Primitive or Secondary, Brain Tumor(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The association between the presence of pruritus, especially centrofacial, and the presence
      of a brain tumor is a widespread notion in the medical community but based on a single
      publication by Andreev et al. in the British Journal of Dermatology published in 1975. No
      other study has studied this association with a rigorous methodology. The aim of this study
      is to evaluate the prevalence of pruritus in patients with one or more primary or secondary
      brain tumor(s), benign(s) or malignant(s).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Monocentric prospective observational study

        -  On the inclusion period

        -  Patients who are seen in radiotherapy consultation and / or department of neurosurgery

        -  Complying with the inclusion criteria, not falling within the exclusion criteria

        -  Re-reading of cerebral MRI (cMRI) with precision on the location(s) of the brain
           tumor(s) according to a predefined anatomic descriptive diagram

        -  Complete the questionnaire by a dermatologist (characteristics of pruritus, brain
           lesion(s), characteristics of the population)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of itching for more than 1 week in a patient with one or more brain tumor(s), primary or secondary, benign(s) or malignant(s).</measure>
    <time_frame>1 year</time_frame>
    <description>Presence of itching for more than 1 week in a patient with one or more brain tumor(s), primary or secondary, benign(s) or malignant(s).</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pruritus</condition>
  <condition>Brain Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who are seen in radiotherapy consultation and / or hospitalization of neurosurgery
        Fulfilling the inclusion criteria, not falling within the exclusion criteria Presence of
        itching for more than 1 week in a patient with one or more brain tumor(s), primary or
        secondary, benign(s) or malignant(s).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age &gt; 18 years

          -  Diagnosis of benign or malignant brain tumor, primary or secondary.

          -  Accepted non-opposition

          -  Realization of a cerebral MRI (cMRI)

        Exclusion criteria:

          -  Age &lt; 18 years

          -  Absence of cerebral imaging of the cMRI type

          -  Absence of non opposition

          -  Realization of a treatment modifying the brain structure (radiotherapy / surgery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurent MISERY</last_name>
    <phone>+332 98 22 33 15</phone>
    <email>laurent.misery@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maxime FOUCHARD</last_name>
    <phone>+332 98 22 33 15</phone>
    <email>maxime.fouchard@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de dermatologie, CHRU BREST</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent MISERY</last_name>
      <email>laurent.misery@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

